Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line
![Creative Medical Technology Holdings](https://nationalstemcelltherapy.com/wp-content/uploads/2022/04/Creative_Medical_Technology_Holdings_Inc_Logo.jpg)
PHOENIX, Oct. 20, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, announced today that through predominantly internal and collaborative development, it has produced an allogenic Cell Line called AlloStem™, which includes a Master Cell Bank and a Drug Master File which shall […]
Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company’s ImmCelz® Product
![Creative Medical Technology Holdings](https://nationalstemcelltherapy.com/wp-content/uploads/2022/04/Creative_Medical_Technology_Holdings_Inc_Logo.jpg)
PHOENIX, April 20, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced progress in developing a reproducible clinical grade product of ImmCelz®. Multiple clinical experiments were performed in which […]